192. A pan-tissue survey of mosaic chromosomal alterations in 948 individuals. Nat Genet 2023, 55(11):1901-1911 (IF 30.8)

Gao T, Kastriti ME, Ljungström V, Heinzel A, Tischler AS, Oberbauer R, Loh PR, Adameyko I, Park PJ, Kharchenko PV.

191. Renin-angiotensin system inhibitor discontinuation in COVID-19 did not modify systemic ACE2 in a randomized controlled trial. iScience 2023, 26(11):108146 (IF 5.8)

Rathkolb V, Traugott MT, Heinzel A, Poglitsch M, Aberle J, Eskandary F, Abrahamowicz A, Mueller M, Knollmueller P, Shoumariyeh T, Stuflesser J, Seeber I, Gibas G, Mayfurth H, Tinhof V, Schmoelz L, Zeitlinger M, Schoergenhofer C, Jilma B, Genser B, Hoepler W, Omid S, Karolyi M, Wenisch C, Oberbauer R, Zoufaly A, Hecking M, Reindl-Schwaighofer R.

190. Prospective assessment of pre-existing and de novo anti-HLA IgE in kidney, liver, lung and heart transplantation. Front Immunol 2023, 14:1179036

Mucha J, Cho A, Weijler AM, Muckenhuber M, Hofmann AG, Wahrmann M, Heinzel A, Linhart B, Gattinger P, Valenta R, Berlakovich G, Zuckermann A, Jaksch P, Oberbauer R, Wekerle T.

189. Monitoring of Sotrovimab-Levels as Pre-Exposure Prophylaxis in Kidney Transplant Recipients Not Responding to SARS-CoV-2 Vaccines. Viruses 2023, 15(8):1624 (IF 4.7)

Aschauer C, Heinzel A, Stiasny K, Borsodi C, Hu K, Koholka J, Winnicki W, Kainz A, Haslacher H, Oberbauer R, Reindl-Schwaighofer R, Weseslindtner L.

188. Sex differences in the survival benefit of kidney transplantation: a retrospective cohort study using target trial emulation. Nephrol Dial Transplant 2023, 39(1):36-44 (IF 4.8)

Geroldinger A, Strohmaier S, Kammer M, Wallisch C, Heinze G, Oberbauer R, Haller MC.

187. A paired-kidney allocation study found superior survival with HLA-DR compatible kidney transplants in the Eurotransplant Senior Program. Kidney Int 2023, 104(3):552-561

de Fijter JW, Dreyer GJ, Mallat MJ, Budde K, Pratschke J, Klempnauer J, Zeier M, Arns W, Hugo C, Rump LC, Hauser I, Schenker P, Schiffer M, Grimm MO, Kliem V, Olbricht CJ, Pisarski P, Banas B, Suwelack B, Hakenberg O, Berlakovich G, Schneeberger S, van de Wetering J, Berger SP, Bemelman F, Kuypers D, Heidt S, Rahmel A, Claas F, Peeters P, Oberbauer R, Heemann U, Krämer BK.

186. Cardiovascular Outcomes in De Novo Kidney Transplant Recipients Receiving Everolimus and Reduced Calcineurin Inhibitor or Standard Triple Therapy: 24-month Post Hoc Analysis From TRANSFORM Study.Transplantation 2023, 107(7):1593-1604. (IF 5.3)

Sommerer C, Legendre C, Citterio F, Watarai Y, Oberbauer R, Basic-Jukic N, Han J, Gawai A, Bernhardt P, Chadban S.

185. Development and Validation of a Prediction Model for Future Estimated Glomerular Filtration Rate in People With Type 2 Diabetes and Chronic Kidney Disease. JAMA Netw Open 2023, 6(4):e231870 (IF 13.8)

Gregorich M, Kammer M, Heinzel A, Böger C, Eckardt KU, Heerspink HL, Jung B, Mayer G, Meiselbach H, Schmid M, Schultheiss UT, Heinze G, Oberbauer R; BEAt-DKD Consortium

184. Different roles of protein biomarkers predicting eGFR trajectories in people with chronic kidney disease and diabetes mellitus: a nationwide retrospective cohort study. Cardiovasc Diabetol 2023, 22(1):74. (IF 8.949)

Kammer M, Heinzel A, Hu K, Meiselbach H, Gregorich M, Busch M, Duffin KL, Gomez MF, Eckardt KU, Oberbauer R; BEAt-DKD consortium

183. Optimum timing of antithymocyte globulin in relation to adoptive regulatory T cell therapy. Am J Transplant 2023, 23(1):84-92.

Muckenhuber M, Mucha J, Mengrelis K, How C, Reindl-Schwaighofer R, Heinzel A, Kainz V, Worel N, Berlakovich G, Edinger M, Oberbauer R, Wekerle T.

SCIENTIFIC COLLABORATIONS